Clinical Trial Update: Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial assesses a combination of Avelumab, Utomilumab, and anti-OX40 PF-04518600 with radiation therapy in patients with advanced solid malignanci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Avelumab (avelumab)
• PF-04518600
• Utomilumab (utomilumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-14